{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=21&q=Hodgkin", "query": { "q": "Hodgkin", "condition": "Lymphoma", "page": 21 }, "page_size": 10 }, "pagination": { "page": 21, "page_size": 10, "total_count": 3804, "total_pages": 381, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=22&q=Hodgkin&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=20&q=Hodgkin&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T03:20:27.525Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01902225", "title": "Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "T-Cell Lymphoma", "Cutaneous Lymphoma" ], "interventions": [ { "name": "Istodax", "type": "DRUG" }, { "name": "Doxil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weiyun Ai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2014-03-04", "completion_date": "2020-04-11", "has_results": false, "last_update_posted_date": "2020-06-09", "last_synced_at": "2026-10-15T03:20:27.525Z", "location_count": 2, "location_summary": "San Francisco, California • Columbus, Ohio", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01902225" }, { "nct_id": "NCT05896163", "title": "A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "maplirpacept (PF-07901801)", "type": "DRUG" }, { "name": "Glofitamab", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2023-08-30", "completion_date": "2026-04-09", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-15T03:20:27.525Z", "location_count": 4, "location_summary": "Kansas City, Kansas • St Louis, Missouri", "locations": [ { "city": "Kansas City", "state": "Kansas" }, { "city": "St Louis", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05896163" }, { "nct_id": "NCT03739814", "title": "Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative", "Recurrent B Acute Lymphoblastic Leukemia", "Refractory B Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Inotuzumab Ozogamicin", "type": "BIOLOGICAL" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Ponatinib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2019-05-08", "completion_date": "2027-02-01", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-15T03:20:27.525Z", "location_count": 279, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 172 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03739814" }, { "nct_id": "NCT05633615", "title": "Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B-Cell Lymphoma", "Grade 3b Follicular Lymphoma", "Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Transformed Follic Lymph to Diff Large B-Cell Lymphoma", "Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma" ], "interventions": [ { "name": "Axicabtagene Ciloleucel", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Lisocabtagene Maraleucel", "type": "BIOLOGICAL" }, { "name": "Mosunetuzumab", "type": "BIOLOGICAL" }, { "name": "Patient Observation", "type": "OTHER" }, { "name": "Polatuzumab Vedotin", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Tisagenlecleucel", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 396, "start_date": "2023-06-12", "completion_date": "2030-06-30", "has_results": false, "last_update_posted_date": "2026-02-02", "last_synced_at": "2026-10-15T03:20:27.525Z", "location_count": 87, "location_summary": "Tucson, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 67 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05633615" }, { "nct_id": "NCT01090414", "title": "An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "Idelalisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 202, "start_date": "2010-03-22", "completion_date": "2018-06-18", "has_results": true, "last_update_posted_date": "2019-08-28", "last_synced_at": "2026-10-15T03:20:27.525Z", "location_count": 18, "location_summary": "Huntsville, Alabama • Los Angeles, California • Palo Alto, California + 12 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01090414" }, { "nct_id": "NCT04644315", "title": "A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms", "Colorectal Neoplasms", "Melanoma", "Pancreatic Neoplasms", "Sarcoma", "Ovarian Neoplasms", "Brain Neoplasms", "Thyroid Neoplasms", "Neuroendocrine Tumors", "Cholangiocarcinoma", "Salivary Gland Neoplasms", "Head and Neck Neoplasms", "Thyroid Cancer, Papillary", "Lymphoma, Large-Cell, Anaplastic", "Neoplasms by Site", "Respiratory Tract Neoplasms", "Thoracic Neoplasms", "Respiratory Tract Diseases", "Carcinoma, Bronchogenic", "Bronchial Neoplasms", "Intestinal Neoplasms", "Gastrointestinal Neoplasms", "Digestive System Neoplasms", "Digestive System Diseases", "Gastrointestinal Diseases", "Colonic Diseases", "Intestinal Diseases", "Central Nervous System" ], "interventions": [ { "name": "Alectinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2021-05-24", "completion_date": "2022-05-16", "has_results": true, "last_update_posted_date": "2023-08-07", "last_synced_at": "2026-10-15T03:20:27.525Z", "location_count": 29, "location_summary": "Culver City, California • Los Angeles, California • Sacramento, California + 21 more", "locations": [ { "city": "Culver City", "state": "California" }, { "city": "Culver City", "state": "California" }, { "city": "Culver City", "state": "California" }, { "city": "Culver City", "state": "California" }, { "city": "Culver City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04644315" }, { "nct_id": "NCT02746952", "title": "Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-cell Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "UCART19", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Institut de Recherches Internationales Servier", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "16 Years to 69 Years" }, "enrollment_count": 25, "start_date": "2016-08-01", "completion_date": "2020-07-28", "has_results": false, "last_update_posted_date": "2021-10-01", "last_synced_at": "2026-10-15T03:20:27.525Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Philadelphia, Pennsylvania • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02746952" }, { "nct_id": "NCT00057447", "title": "Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Interferon Gamma-1b", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "InterMune", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 24, "start_date": "2003-03", "completion_date": "2004-06", "has_results": false, "last_update_posted_date": "2007-11-01", "last_synced_at": "2026-10-15T03:20:27.525Z", "location_count": 1, "location_summary": "Brisbane, California", "locations": [ { "city": "Brisbane", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00057447" }, { "nct_id": "NCT02061449", "title": "Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cutaneous T-cell Lymphoma" ], "interventions": [ { "name": "Romidepsin", "type": "DRUG" }, { "name": "Poly ICLC", "type": "DRUG" }, { "name": "Focal lesional radiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2014-03", "completion_date": "2018-11-05", "has_results": false, "last_update_posted_date": "2018-12-24", "last_synced_at": "2026-10-15T03:20:27.525Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02061449" }, { "nct_id": "NCT00147485", "title": "A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "AG-024322", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2004-12", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2008-08-18", "last_synced_at": "2026-10-15T03:20:27.525Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Philadelphia, Pennsylvania", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00147485" } ] }